NCT03502746 - Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

May 11, 2022

Study Completion Date

November 9, 2023

Conditions

Mesothelioma, Malignant

Interventions

DRUG

Nivolumab

Nivolumab 240mg, IV over 30 minutes.

DRUG

Ramucirumab

8mg/kg, IV over 60 minutes.

Trial Locations (4)

University of Maryland, Baltimore

Moffitt Cancer Center, Tampa

Karmanos Cancer Center (Wayne State University), Detroit

HealthPartners Institute Regions Cancer Care Center, Minneapolis